BACKGROUND Chatbot-based interventions have shown promise in common mental health conditions such as depression and anxiety. However, their application in schizophrenia (SZ), particularly for psychiatric medication counseling, remains extremely limited. OBJECTIVE This study aimed to investigate the effects of a rule-based psychiatric medication counseling chatbot on clinical and patient-reported outcomes in patients with SZ. METHODS A total of 31 outpatients with SZ participated in a single-group pre–post study. Participants used a rule-based chatbot via a mobile app for 3 months. The chatbot provided structured guidance on antipsychotic medications, including side effects, management strategies, medication use, expected therapeutic effects and duration of medication. Primary outcomes included medication adherence (Adherence Rating Scale [ARS]), subjective well-being (Subjective Well-being under Neuroleptic Treatment Scale [SWN]), and side effects (Udvalg for Kliniske Undersøgelser Side Effect Rating Scale [UKU]). Secondary outcomes included psychopathology (PANSS), functioning (SOFAS), and insight (SUMD-K). RESULTS A total of 31 participants (mean age 33.91 years, SD 11.60; 20 males) completed the study. Medication adherence (ARS) showed a trend-level increase (4.77 vs 4.94, t=2.02, p=.057) but did not reach statistical significance. Among SWN subdomains, self-control improved significantly (mean difference 1.48, 95% CI 0.03 to 2.94, p=.045). UKU total severity scores decreased significantly (19.48 vs 14.52, mean difference −4.96, 95% CI −8.53 to −1.40, p=.008), driven by reductions in psychic (mean difference −1.97, 95% CI −3.52 to −0.41, p=.015) and miscellaneous symptom domains (mean difference −1.58, 95% CI −3.06 to −0.10, p=.037). Among secondary outcomes, PANSS positive symptoms decreased significantly (11.39 vs 10.35, mean difference −1.04, 95% CI −1.90 to −0.17, p=.021), whereas functioning (SOFAS) and insight (SUMD-K) did not change significantly. Older age (β=0.157, p=.017) and living with family members (β=4.304, p=.047) were associated with improvements in physical functioning, and greater chatbot use was associated with improvements in social integration (β=0.150, p=.029) and socio-occupational functioning (β=0.082, p=.024). CONCLUSIONS A rule-based psychiatric medication counseling chatbot was associated with modest but significant improvements in subjective well-being and perceived side effect burden in patients with SZ, while its impact on medication adherence and broader clinical outcomes was limited. These findings suggest that chatbot-based interventions may serve as a useful adjunctive tool in SZ care, particularly for addressing medication-related concerns. CLINICALTRIAL Clinical Research Information Service (CRIS) KCT0011949; https://cris.nih.go.kr (registration number: KCT0011949)